Zekeriya Hannarici
Overview
Explore the profile of Zekeriya Hannarici including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buyukbayram M, Hannarici Z, Duzkopru Y, Turhan A, Caglar A, Coban Esdur P, et al.
Breast Cancer (Dove Med Press)
. 2024 Jul;
16:329-339.
PMID: 38974895
Objective: Hormone positive breast cancer is a tumor with high mortality. Combining antihormonal therapy with cyclin dependent kinase 4/6 inhibitors (CDK4/6i) has resulted in longer survival. The effect of inflammatory...
2.
Buyukbayram M, Hannarici Z, Yilmaz A, Turhan A, Caglar A, Coban Esdur P, et al.
Lung Cancer Manag
. 2024 May;
13(1):LMT66.
PMID: 38818368
The tumor microenvironment of NSCLC with driver mutations, such as , and , is less inflammatory. This retrospective study included 38 patients with NSCLC driver mutations. The relationship between clinical...
3.
Buyukbayram M, Hannarici Z, Turhan A, Caglar A, Coban Esdur P, Bilici M, et al.
BMC Cancer
. 2024 May;
24(1):626.
PMID: 38783223
Background: Cervical cancer is a tumor with high morbidity and mortality. The importance of inflammatory and metabolic parameters affecting progression-free survival (PFS) and overall survival (OS) has been investigated more...
4.
Hannarici Z, Yilmaz A, Buyukbayram M, Turhan A, Caglar A, Bilici M, et al.
Future Oncol
. 2023 May;
19(4):315-325.
PMID: 37125596
To demonstrate the prognostic importance of glucose-to-lymphocyte ratio (GLR) in metastatic gastric cancer (mGC). Retrospectively, 159 mGC patients were enrolled. Kaplan-Meier curve and Cox regression analysis were used to determine...
5.
Hannarici Z, Yilmaz A, Buyukbayram M, Tekin S, Bilici M
Melanoma Res
. 2022 Jun;
32(4):302.
PMID: 35703446
No abstract available.
6.
Hannarici Z, Yilmaz A, Buyukbayram M, Turhan A, Tekin S, Bilici M
J Oncol Pharm Pract
. 2022 Feb;
28(8):1902-1905.
PMID: 35200056
Introduction: Granulocyte colony-stimulating factors (G-CSF) are utilized both in the treatment and prophylaxis of chemotherapy-induced neutropenia. Lipegfilgrastim is a long-acting G-CSF. Albeit it provides ease of administration compared to short-acting...
7.
Hannarici Z, Ucler R, Yildiz S, Usul Soyoral Y, Alay M
J Clin Densitom
. 2022 Feb;
25(3):343-348.
PMID: 35168896
Histological evidence of osteodystrophy and osteopenia is encountered in most patients who have undergone successful renal transplantation. Renal transplantation may be beneficial for correcting uremia-related problems in end-stage renal disease...
8.
Hannarici Z, Yilmaz A, Buyukbayram M, Tekin S, Bilici M
Melanoma Res
. 2021 Sep;
31(6):566-574.
PMID: 34570023
It is well-known that inflammation plays a significant role in cancer formation and prognosis. Both lymphocyte count and red cell distribution width (RDW) has been used to predict prognosis in...
9.
Yilmaz A, Simsek M, Hannarici Z, Buyukbayram M, Bilici M, Tekin S
Future Oncol
. 2021 Aug;
17(33):4545-4559.
PMID: 34431372
To show the prognostic significance of the glucose-to-lymphocyte ratio (GLR) in hepatocellular carcinoma (HCC). A total of 150 patients with advanced HCC who were treated with sorafenib in our center...